KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.

Creative Commons License

KATO K., SHAH M., ENZINGER P., BENNOUNA J., SHEN L., ADENIS A., ...More

Future oncology (London, England), vol.15, pp.1057-1066, 2019 (SCI-Expanded, Scopus)

  • Publication Type: Article / Article
  • Volume: 15
  • Publication Date: 2019
  • Doi Number: 10.2217/fon-2018-0609
  • Journal Name: Future oncology (London, England)
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1057-1066
  • Keywords: chemotherapy, esophageal cancer, esophagogastric junction cancer, gastrointestinal/esophageal, immunotherapy, PD-1, PD-L1, pembrolizumab, squamous cell carcinoma of the esophagus, SQUAMOUS-CELL CARCINOMA, GASTROESOPHAGEAL JUNCTION, SUPPORTIVE CARE, GASTRIC-CANCER, OPEN-LABEL, ADENOCARCINOMA, PLUS, PACLITAXEL, IRINOTECAN, BLOCKADE
  • Open Archive Collection: AVESIS Open Access Collection
  • Istanbul University-Cerrahpasa Affiliated: No